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Background
Riociguat is the first oral, soluble guanylate cyclase sti-
mulator currently under review for the treatment of pul-
monary hypertension (PH), a progressive disease with
high mortality [1-7]. The present pooled analysis
assessed the pharmacokinetics of riociguat and its meta-
bolite M1 (BAY 60-4552) in individuals with hepatic
impairment (Child–Pugh A or B) and healthy controls.
The safety and tolerability of riociguat were evaluated.
Methods
Two non-randomized, non-blinded, observational studies
with group stratification were included in the analysis. The
studies were conducted in a single centre in Germany, in
accordance with Good Clinical Practice and industry
guidelines [8,9]. Individuals with liver cirrhosis (Child–
Pugh A, n = 16; Child–Pugh B, n = 16) and 32 healthy
age-, weight- and sex-matched volunteers received a single
oral tablet dose of riociguat 1 mg. Dense sampling was
performed for pharmacokinetic parameters.
Results
Sixty-four participants (42 men and 22 women; mean
age, 55.1 years [range, 35–72 years]) received riociguat
and completed the study according to protocol. Owing to
the rapid absorption of riociguat (median time to reach
maximum concentration in plasma [Cmax], ≤ 1.5 hours in
all groups), mean dose- and body-weight-normalized
Cmax values for total riociguat were similar in all groups
(Table 1). Mean half-life of total riociguat was longer in
the Child–Pugh B group than in the Child–Pugh A
group and the controls (Table 1). Exposure (dose- and
body-weight-normalized area under the plasma concen-
tration–time curve [AUCnorm]) to total riociguat was ele-
vated in Child–Pugh B but not Child-Pugh A individuals
compared with controls (Table 1, Figure 1). Antagonizing
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Table 1 Pharmacokinetic parameters of riociguat in plasma following a single oral dose of riociguat 1 mg
Parameter Child–Pugh A (n = 16) Child–Pugh B (n = 16) Control A (n = 16) Control B (n = 16)
AUC, μg·h/L 371.0 (74) 458.9 (62) 349.9 (67) 300.9 (92)
Cmax, μg/L 42.67 (37) 43.27 (39) 42.67 (23) 38.68 (30)
AUCnorm, kg·h/L 30.9 (75) 36.6 (65) 29.1 (67) 23.9 (94)
Cmax,norm, kg/L 3.56 (33) 3.45 (26) 3.55 (20) 3.07 (23)
t½, h 9.19 (53) 13.7 (50) 9.02 (63) 7.54 (86)
Values are geometric means (percentage coefficient of variation). AUC, area under the plasma concentration–time curve from time 0 to infinity; AUCnorm, AUC
divided by dose per kilogram of body weight for total riociguat; Cmax, maximum concentration in plasma; Cmax,norm, Cmax divided by dose per kilogram of body
weight for total riociguat; t½, terminal elimination half-life for total riociguat.
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effects – reduced rate of formation and impaired M1
elimination – led to relatively small differences in overall
exposure to M1 in the Child–Pugh A and B groups and
their controls. Results for unbound riociguat and M1
were similar to those for total riociguat and M1. No ser-
ious or severe adverse events were reported. The most
common drug-related adverse event was headache. There
was no difference in safety or tolerability between study
groups. Riociguat AUC and Cmax ranges in patients with
hepatic impairment overlapped those previously observed
in healthy volunteers and patients with PH [2,3].
Conclusion
Child–Pugh A individuals had similar plasma riociguat
concentrations to controls. Child–Pugh B individuals had
a higher exposure to riociguat than those in the other
groups; particular care should be exercised during indivi-
dual dose titration in patients with moderate hepatic
impairment.
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Figure 1 Box-and-whisker plot of riociguat AUCnorm (kg·h/L) after a single oral dose of riociguat 1 mg. Box, 25th–75th percentile; vertical line, 10th–
90th percentile; horizontal line, median; more extreme values are plotted as points; individuals eligible for pharmacokinetic analysis, n = 64; AUCnorm,
area under the plasma concentration–time curve from time 0 to infinity divided by dose per kilogram of body weight for total riociguat.
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